Proviral Sequencing Driven Development of Enhanced IPDAv2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials

Proviral 测序驱动增强型 IPDAv2 的开发，覆盖全球 HIV-1 M 组，以支持全球治疗和临床试验

• 批准号: 10927086
• 负责人: GREGORY LAIRD
• 金额: $ 200万
• 依托单位: ACCELEVIR DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10927086
• 关键词: Base Sequence; Biological Assay; Clinical; Clinical Research; Clinical Trials; Contracts; Development; Genetic Transcription; Goals; HIV; HIV-1; Intervention; Length; Monitor; Proviruses; Recombinants; analytical tool; commercialization; design; programs; prospective

The objective of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. The assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and in prospective clinical trials. An additional goal of the program is to develop secondary assays that are not tissue culture-based and discriminate between actively transcribed and latent full-length proviruses. This contract is to develop and validate version 2 of the IPDA for use across major HIV-1 Group M subtypes and recombinants.

该计划的目的是开发和商业化基于序列的HIV储藏测定法，以进行临床HIV治疗干预措施。该测定应被设计为一种分析工具，以监测临床研究和前瞻性临床试验中复制能力的HIV水库的大小。该计划的另一个目标是开发不是基于组织培养的次要测定，并区分主动转录和潜在的全长病毒。该合同是为了开发和验证IPDA版本2，以供主要的HIV-1组M子类型和重组者使用。